Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine

Epalinges, Switzerland, September 23, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today as part of the Research Agreement signed in May 2020 with Baylor College of Medicine and Texas Children’s Center for Vaccine Development, that Mymetics has piloted and successfully produced different virosome formulations which incorporate the SARS-CoV-2 recombinant protein. The Company has now shipped these formulations to Baylor College of Medicine where they will be tested and compared in a pre-defined preclinical model in accordance with the Research Agreement signed between the parties in May 2020. Results are expected in three months.

Media Name Media Type Description Download
Press Release PDF Download